"Building a Biotech Company" with Lonnie Moulder ‘97
September 28, 2016: 6:30 PM - 9:00 PM
Come join us for a speaking event with Lonnie Moulder, experienced biotech executive and Co-Founder and CEO of TESARO, Inc. (NASDAQ: TSRO).
650 E. Kendall Street
The Booth Alumni Club of Boston, in conjunction with the University of Chicago Alumni Club of Boston, is pleased to sponsor a night with Lonnie Moulder, an alumni of the Booth School of Business and CEO and Co-Founder of TESARO, Inc. (NASDAQ: TSRO).
The evening will take place at Cafe ArtScience in Cambridge and will include a networking cocktail hour followed by Mr. Moulder speaking on "Building a Biotech Company."
We hope you can join us!
Price is $30 per person.
Walk-ins welcome. Please email Denise.Dilley@chicagobooth.edu
Lonnie Moulder (Speaker) '97
CEO and Co-Founder, TESARO, Inc.
Lonnie Moulder is an experienced biotechnology executive and an alumnus of the University of Chicago Booth School of Business. Prior to founding TESARO, Mr. Moulder served as Vice Chairman of the Board of Directors, President, and Chief Executive Officer of Abraxis BioScience, Inc. and as President and Chief Executive Officer of its wholly owned operating subsidiary, Abraxis BioScience, LLC and the Abraxis Oncology division. Before that, he served as Vice Chairman and Executive Vice President of Eisai Corporation of North America, from January 2008 until January 2009, following Eisai Co. Ltd.'s acquisition of MGI Pharma, Inc., a pharmaceutical company, in January 2008. Mr. Moulder served as President and Chief Executive Officer and as member of the Board of Directors of MGI PHARMA, Inc. from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA, Inc. in September 1999 as Executive Vice President and was promoted to President and Chief Operating Officer in May 2002. Mr. Moulder earned a Bachelor of Science degree in pharmacy from Temple University. He currently serves as Chairman of the Board of Directors of Trevena, Inc., as trustee of Temple University, and is on the Board of the Fox Chase Cancer Center. He also served as a director of Cubist Pharmaceuticals, Inc. through the sale of the company in 2015.
Brendan Reardon, '14